BR112015020924A2 - anilina substituída com n-heteroaril derivada como antivirais de hcv - Google Patents

anilina substituída com n-heteroaril derivada como antivirais de hcv

Info

Publication number
BR112015020924A2
BR112015020924A2 BR112015020924A BR112015020924A BR112015020924A2 BR 112015020924 A2 BR112015020924 A2 BR 112015020924A2 BR 112015020924 A BR112015020924 A BR 112015020924A BR 112015020924 A BR112015020924 A BR 112015020924A BR 112015020924 A2 BR112015020924 A2 BR 112015020924A2
Authority
BR
Brazil
Prior art keywords
heteroaryl substituted
substituted aniline
aniline derived
hcv antivirals
formula
Prior art date
Application number
BR112015020924A
Other languages
English (en)
Inventor
Plancher Jean-Marc
James Weikert Robert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015020924A2 publication Critical patent/BR112015020924A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/40—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

1/1 resumo anilina substituída com n-heteroaril derivada como antivirais de hcv a presente invenção divulga compostos de fórmula (i): em que as variáveis na fórmula i são definidas como descritas aqui. composições farmacêuticas contendo tais compostos e fórmulas e métodos para uso dos compostos de fórmula i na prevenção ou tratamento de infecção por hcv também são divulgados.
BR112015020924A 2013-03-05 2014-02-27 anilina substituída com n-heteroaril derivada como antivirais de hcv BR112015020924A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772930P 2013-03-05 2013-03-05
PCT/EP2014/053781 WO2014135423A1 (en) 2013-03-05 2014-02-27 N-heteroaryl substituted aniline derivatives as hcv-antivirals

Publications (1)

Publication Number Publication Date
BR112015020924A2 true BR112015020924A2 (pt) 2017-07-18

Family

ID=50184917

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015020924A BR112015020924A2 (pt) 2013-03-05 2014-02-27 anilina substituída com n-heteroaril derivada como antivirais de hcv

Country Status (11)

Country Link
US (1) US9382218B2 (pt)
EP (1) EP2964620A1 (pt)
JP (1) JP2016510047A (pt)
KR (1) KR20150112035A (pt)
CN (1) CN104995179A (pt)
BR (1) BR112015020924A2 (pt)
CA (1) CA2898162A1 (pt)
HK (1) HK1216639A1 (pt)
MX (1) MX2015010790A (pt)
RU (1) RU2015136817A (pt)
WO (1) WO2014135423A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE15667T1 (de) * 1980-06-27 1985-10-15 Beiersdorf Ag Neue substituierte 3,5-diamino-1,2,4-oxadiazole und 3,5-diamino-1,2,4-thiadiazole, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
AU2006244203B2 (en) * 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
CN101801964A (zh) * 2007-05-22 2010-08-11 艾其林医药公司 杂芳基取代的噻唑及其作为抗病毒剂的用途
US20140010783A1 (en) * 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
BR112015017414A2 (pt) * 2013-01-23 2017-07-11 Hoffmann La Roche derivados de triazol antivirais

Also Published As

Publication number Publication date
RU2015136817A (ru) 2017-04-10
US20160000763A1 (en) 2016-01-07
CA2898162A1 (en) 2014-09-12
KR20150112035A (ko) 2015-10-06
HK1216639A1 (zh) 2016-11-25
US9382218B2 (en) 2016-07-05
CN104995179A (zh) 2015-10-21
WO2014135423A1 (en) 2014-09-12
JP2016510047A (ja) 2016-04-04
MX2015010790A (es) 2015-11-26
EP2964620A1 (en) 2016-01-13

Similar Documents

Publication Publication Date Title
BR112015021429A2 (pt) compostos antivirais
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
BR112015004113A2 (pt) 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112019007108A2 (pt) misturas herbicidas
BR112014017749A8 (pt) Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
BR112018005194A2 (pt) processo de composto antifúngico
BR112016014412A2 (pt) Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo
BR112012030923B8 (pt) Composto derivado de piperidinona como inibidor de mdm2 e composição farmacêutica compreendendo o mesmo
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112014018943A8 (pt) Composições pesticidas e processos relacionados as mesmas
BR112017012197A2 (pt) composto, composição herbicida, mistura herbicida e método para controlar o crescimento de vegetação indesejada
BR112014008616A2 (pt) compostos antivirais
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
BR112016017747A2 (pt) Agente de intensificação de efeito de reabilitação pós lesão de nervo compreendendo derivados de éter de alquila ou sal do mesmo
BR112018077075A2 (pt) heterociclos de biarilmetila
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
BR112015023829A2 (pt) composto de amidina e seu uso
BR112015000011A2 (pt) compostos de triazol como medicamentos antivirais
BR112015020952A2 (pt) compostos antivirais
BR112016022749A2 (pt) compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2
BR112015020834A2 (pt) novos derivados hidroquinolina-2-ona como inibidores de aldosterona sintetase (cyp1 1 b2 ou cyp1 1 b1)

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]